The global cell line development market size was valued at USD 4.81 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 9.81% from 2023 to 2030. Cell line development (CLD) process is expected to be in high demand as the biopharmaceutical sector expands. The majority of biopharma businesses uses cells as an expression host for the synthesis of recombinant monoclonal antibodies and proteins. The availability of enhanced technologies to manufacture novel cell lines and an increase in demand for monoclonal antibodies and cancer therapies are projected to drive market expansion in coming years.
COVID-19 benefited the CLD market as a result of increased demand for vaccine research. According to a study published in March 2022, named “A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry”, the researchers have described the development of a suitable human cell line to conduct high-throughput testing of antiviral drugs that target the coronavirus 2 that causes severe acute respiratory syndrome (SARS-CoV-2). Two key host proteins necessary for viral entry, angiotensin-converting enzyme 2 (ACE2) & transmembrane serine protease 2 (TMPRSS2), were designed to express at high levels in the human lung cancer cell line A549. As a result, more cell lines were and are still being produced to handle COVID-19, which has significantly impacted the market during the pandemic period.
During the projection period, the expiration of blockbuster medications such as Lantus, Abilify, Namenda, & Androgel is likely to drive the development of new biosimilars. The growing number of R&D activities for biosimilars and biologic products, is predicted to drive demand for cell lines for large-scale production. In recent years, the US Food & Drug Administration (FDA) has authorized approximately 15 new proteins per year, including therapeutic & recombinant proteins. As a result, the rising need for innovative pharmaceuticals, vaccines, biosimilars, as well as therapeutic proteins is likely to drive the growth of the CLD market throughout the forecast period.
Cancer has been increasingly widespread in the last 10 years as a result of changes in dietary practices, a lack of physical exercise, and overall changes in lifestyle. Furthermore, as vaccine production expands & technology progresses, the requirement for cell line creation will rise. According to the American Cancer Society estimate, the overall number of new cancer cases in 2023 is approximately 1,958,310 and 609,820 cancer death in the U.S. Furthermore, due to the rising use of cell lines in the manufacturing of biological cancer drug substances, the CLD market is likely to grow over the forecast period. However, the presence of regulatory framework and ethical concern related to stem cell-based research restrain the market growth to a certain extend.
Moreover, the growing acceptance of novel biopharmaceutical medications, as well as a growth in the prevalence of chronic diseases, will drive demand for biopharmaceutical products. Innovative product offerings will arise from the increased use of cutting-edge technology, such as bio-recombinant proteins, in the treatment of numerous chronic diseases. The safety and efficacy of biopharmaceutical products, as well as their ability to cure diseases that were previously incurable, will increase the rate of adoption for CLD and further boost the market growth.
The reagents and media segment held the largest market share of 43.78% in 2022. due to its wide applications in areas such as bio production, regenerative medicines, tissue engineering, drug discovery, and toxicity testing. Reagent and media are indispensible component of cell culture & cell line development process and is cost intensive in nature. Hence, propelling the segment growth.
The services segment is expected to witness the fastest CAGR of 10.64% from 2023 to 2030. CLD services are expected to rise over time due to the rising demand for monoclonal antibodies, patent expiration of blockbuster biologics, increasing demand for effective cancer therapeutics and technological advancement in the field of CLD. Furthermore, the increasing trend of biologics outsourcing as well as rising approval & demand for biologics and biosimilars, are all providing the market with enormous growth opportunities.
The mammalian cell line segment held the largest market share of 72.62% in 2022. Cell line formation begins with organs or tissues obtained from mammals or non-mammalian sources. Cell line source selection is required for the production of commercially viable stable cell lines. Mammalian cell lines are most widely employed for the synthesis of monoclonal antibodies, vaccines, & biologics due to their increased complex protein expression capabilities. There are approximately 4,000 mammalian cell lines available, and research is ongoing to introduce a few more. Over the projected period, all of the aforementioned facts are expected to create a profitable growth framework for CLD from mammalian sources.
Mammalian cell culture techniques are developed to produce vaccines for diseases such as mumps, rubella, and measles in humans, and foot & mouth diseases in veterinary care. It is the fastest-growing segment due to efficient production of biopharmaceuticals by mammalian cell lines as they are capable of providing complex proteins expression similar to humans. This is expected to increase the revenue share of mammalian cell line source in thand e CLD market.
The recombinant cell lines segment held the largest market share of 31.79% in 2022. due to its extensive use in biologics production processes, gene activation, and protein interactions. In the upcoming years, it is also projected that increased demand would fuel the need for drug screening and toxicity testing. The main driver of the rising adoption of recombinant proteins throughout the projection period is the demand for biologics to treat cancer and autoimmune illnesses. These products include enzymes, blood components, hormones, monoclonal antibodies, and chemicals connected to antibodies. Over 400 of the 650 protein therapies that have received global approval are recombinant products.
The hybridomas segment is expected to witness the fastest CAGR of 10.10% from 2023 to 2030. The market for hybridomas is expected to show lucrative growth over the forecast period due to advantages associated with it such as ability to grow continuously, combination of two different types of cells, and production of pure antibodies on a large-scale. In addition, continuous advancement in the hybridoma technology such as use of feeder layers that consist of murine peritoneal cells and macrophages derived from mouse is expected to fuel this market growth over the forecast period.
The bioproduction segment held the largest market share of 46.30% in 2022. This attributed to the increased demand for drugs and vaccine production. The bioproduction technology area comprises the production of biologics-based treatment drugs such as vaccines, therapeutic proteins, cell therapies, along with gene therapies. The most common uses of bioproduction are producing biologics & vaccine, and demand is predicted to grow dramatically in the future owing to the increase in viral & communicable illnesses, particularly in developing nations.
The tissue engineering segment is expected to witness the fastest CAGR of 10.53% from 2023 to 2030. Growing adoption rates of tissue engineering in patient treatment such as implantation of bladders, skin grafts, small arteries, trachea, and cartilage, and increasing awareness related to personalized medicine are the factors contributing the market growth. In addition, rising awareness pertaining to regenerative medicines in which tissue or organ is safely grown in laboratory conditions with the help of cell culture techniques and then implanted are further expected to provide growth platform to this segment.
North America held the largest market share of 39.22% of the global cell line development market in 2022. Owing to the increasing adoption rates of cell culture techniques due to advantages associated with it such as cost effectiveness and high productivity. The presence of sophisticated healthcare infrastructure, growing demand for biologics and increasing awareness related to cell therapy coupled with relatively higher healthcare expenditure levels in the region are the factors contributing towards the market growth.
Asia Pacific is expected to experience the fastest CAGR of 11.61% from 2023 to 2030 Key factors such as presence of untapped opportunities, economic development, improving healthcare infrastructure, and favorable initiatives by government and manufacturers in biotechnology sector are some factors accounting for this rapid growth. Furthermore, increasing median age of the population, rising production of vaccines, therapeutic proteins and others are the factors contributing to the overall growth of CLD market.
The continuous demand for CLD products by multiple application has created numerous market opportunities for major players to capitalize on. For instance, in May 2023, Researchers at FUJIFILM Diosynth Biotechnologies have enhanced their cell line development methods by using Cyto-Mine, Sphere Fluidics' next-generation single-cell analysis device. Some prominent players in the global cell line development market include:
Thermo Fisher Scientific Inc.
Merck KGaACorning Inc.
Market size value in 2023
USD 5.24 billion
Revenue forecast in 2030
USD 10.09 billion
CAGR of 9.81% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product & services, source, type of cell lines, application, region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; Germany; U.K.; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait
Key companies profiled
Thermo Fisher Scientific Inc., Corning Inc., Lonza, Creative BioLabs., WuXi PharmaTech, Sartorius AG, Merck KGaA, Advanced Instruments, Berkeley Lights, Danaher
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, grand view research has segmented the global cell line development market report based on product & services, source, type of cell lines, application, and region:
Product & Service Outlook (Revenue, USD Million, 2018 - 2030)
Reagents and media
Accessories and consumables
Source Outlook (Revenue, USD Million, 2018 - 2030)
Mammalian cell line
Non-mammalian cell line
Type of Cell Lines Outlook (Revenue, USD Million, 2018 - 2030)
Recombinant cell lines
Continuous cell lines
Primary cell lines
Application Outlook (Revenue, USD Million, 2018 - 2030)
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global cell line development market size was estimated at USD 4.81 billion in 2022 and is expected to reach USD 5.24 billion in 2023.
b. The global cell line development market is expected to grow at a compound annual growth rate of 9.81% from 2023 to 2030 to reach USD 10.09 billion by 2030.
b. Reagents and media accounted for the largest revenue share of 43.78% in 2022, due to increasing bio-production. Additionally, these products are cost-intensive nature and have repetitive use in the production of biologics hence accounted for the largest revenue share.
b. Some of the key players operating in this market are Thermo Fisher Scientific Inc., Corning Inc., Lonza, Creative BioLabs., WuXi PharmaTech, Sartorius AG, Merck KGaA, Advanced Instruments, Berkeley Lights, and Danaher.
b. The availability of enhanced technologies to manufacture novel cell lines and an increase in demand for monoclonal antibodies and cancer therapies are projected to drive market expansion in coming years.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."